Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Ann Hepatol ; 17(5): 795-801, 2018 Aug 24.
Article in English | MEDLINE | ID: mdl-30145567

ABSTRACT

INTRODUCTION AND AIM: Transient elastography is gaining popularity as a non-invasive method for predicting liver fibrosis, but inter observer agreement and factors influencing reproducibility have not been adequately assessed. MATERIAL AND METHODS: This cross-sectional study was conducted at Specialized Medical Hospital and the Egyptian Liver Foundation, Mansoura, Egypt. The inclusion criteria were: age older than 18 years and chronic infection by hepatitis C. The exclusion criteria were the presence of ascites, pacemaker or pregnancy. Three hundred and fifty-six patients participated in the study. Therefore, 356 pairs of exams were done by two operators on the same day. RESULTS: The overall inter observer agreement ICC was 0.921. The correlation the two operators was excellent (Spearman's value q = 0.808, p < 0.001). Inter-observer reliability values were κ = 0.557 (p < 0.001). A not negligible discordance of fibrosis staging between operators was observed (87 cases, 24.4%). Discordance of at least one stage and for two or more stages of fibrosis occurred in 60 (16.9%) and 27 cases (7.6%) respectively. Obesity (BMI ≥ 30 kg/m2) is the main factor associated with discordance (p = 0.002). CONCLUSION: Although liver stiffness measurement has had an excellent correlation between the two operators, TE presented an inter-observer variability that may not be negligible.


Subject(s)
Elasticity Imaging Techniques , Hepatitis C, Chronic/complications , Liver Cirrhosis/diagnostic imaging , Obesity/complications , Adult , Body Mass Index , Cross-Sectional Studies , Egypt , Female , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/virology , Humans , Liver Cirrhosis/virology , Male , Middle Aged , Obesity/diagnosis , Observer Variation , Predictive Value of Tests , Reproducibility of Results
2.
Ann Hepatol ; 16(6): 862-873, 2017.
Article in English | MEDLINE | ID: mdl-29055924

ABSTRACT

Background and rationale for the study. Liver biopsy is the golden standard for staging liver fibrosis, but it may be accompanied by complications. Because of this complication, the aim of this study is to evaluate a simple noninvasive score to assess hepatic fibrosis in chronic hepatitis C genotype 4 patients which is very may have an important in diagnosis and therapeutic decision. This score [HA vascular (HAV) score] is a combination of direct markers [hyaluronic acid (HA) and vascular endothelial growth factor (VEGF)] and indirect markers [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)]. RESULTS: Samples were collected from 220 patients (F0-F4): an estimated group (n = 120) and a validated group (n = 100). HA and VEGF levels, HCV RNA, liver function tests, platelet counts were assayed, Fibroscan was done and liver biopsy was taken and the stage of liver fibrosis and the grade of inflammatory activity was calculated according to Metavir score system. HA vascular (HAV) score = -35.1 + 0.14 (HA) (ng/L) + 0.03 (VEGF) (pg/mL) + (-6.7) [AAR (AST/ALT ratio)]. The HAV score produced areas under curve of 0.979 and 0.994 for significant (F2-F4) and advanced fibrosis (F3-F4) (cut off = 0.583 and 6.3, respectively). Surprisingly, the validation study of this score gave very good values of AUCs i.e. 0.990, 0.996 and 0.995 for significant, advanced and liver cirrhosis. CONCLUSIONS: Our developed score can not only help to assess liver fibrosis staging effectively but also avoid the invasiveness and the limitations of liver biopsy in Egyptian hepatitis C virus patients.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Decision Support Techniques , Hepatitis C, Chronic/complications , Hyaluronic Acid/blood , Liver Cirrhosis/diagnosis , Vascular Endothelial Growth Factor A/blood , Adult , Area Under Curve , Biomarkers/blood , Biopsy , Case-Control Studies , Egypt , Elasticity Imaging Techniques , Female , Genotype , Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis C, Chronic/diagnosis , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Male , Middle Aged , Predictive Value of Tests , ROC Curve , Reproducibility of Results , Severity of Illness Index , Young Adult
3.
Ann Hepatol ; 12(1): 44-53, 2013.
Article in English | MEDLINE | ID: mdl-23293193

ABSTRACT

BACKGROUND: Several noninvasive predictive models were developed to substitute liver biopsy for fibrosis assessment. AIM: To evaluate the diagnostic value of fibronectin which reflect extracellular matrix metabolism and standard liver functions tests which reflect alterations in hepatic functions. MATERIAL AND METHODS: Chronic hepatitis C (CHC) patients (n = 145) were evaluated using ROC curves and stepwise multivariate discriminant analysis (MDA) and was validated in 180 additional patients. Liver biochemical profile including transaminases, bilirubin, alkaline phosphatase, albumin, complete blood count were estimated. Fibronectin concentration was determined using monoclonal antibody and ELISA. RESULTS: A novel index named fibronectin discriminant score (FDS) based on fibronectin, APRI and albumin was developed. FDS produced areas under ROC curves (AUC) of 0.91 for significant fibrosis and 0.81 for advanced fibrosis. The FDS correctly classified 79% of the significant liver fibrosis patients (F2-F4) with 87% sensitivity and 75% specificity. The relative risk [odds ratio (OR)] of having significant liver fibrosis using the cut-off values determined by ROC curve analyses were 6.1 for fibronectin, 4.9 for APRI, and 4.2 for albumin. FDS predicted liver fibrosis with an OR of 16.8 for significant fibrosis and 8.6 for advanced fibrosis. The FDS had similar AUC and OR in the validation group to the estimation group without statistically significant difference. CONCLUSION: FDS predicted liver fibrosis with high degree of accuracy, potentially decreasing the number of liver biopsy required.


Subject(s)
Aspartate Aminotransferases/blood , Fibronectins/blood , Hepatitis C, Chronic/blood , Liver Cirrhosis/blood , Liver/pathology , Adult , Biomarkers , Biopsy, Large-Core Needle , Discriminant Analysis , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Female , Hepatitis C, Chronic/diagnostic imaging , Hepatitis C, Chronic/pathology , Humans , Liver/diagnostic imaging , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/pathology , Logistic Models , Male , Middle Aged , Platelet Count , Predictive Value of Tests , Prospective Studies , ROC Curve , Reproducibility of Results , Serum Albumin/analysis , Severity of Illness Index , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL